Temasek backs $75m Series B for US-based Viela Bio

Temasek backs $75m Series B for US-based Viela Bio

REUTERS/Edgar Su

US-based clinical-stage biotechnology company Viela Bio has raised $75 million in a Series B financing round backed by existing investor Singapore’s state-owned investment firm Temasek Holdings, according to a statement.